All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
2 warning events since 2020; the latest 2025-01-15.
From the record
Gain Therapeutics, Inc.'s filings since 2020 show 2 warning events: a notice about its exchange listing (8-K item 3.01, 2 times, the latest 2025-01-15) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+24.1% a year over 4 filed years; profitable in 0 of 4.
From the record
Gain Therapeutics, Inc.'s 4 filed years say what it did: revenue went from $29 thousand in fiscal 2020 to $55 thousand in fiscal 2023, up 24.1% a year; it rose in 1 of 3 years; the deepest fall was 67% from fiscal 2021 to fiscal 2023; net income was positive in 0 of 4 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 3.5/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Gain Therapeutics, Inc.'s shareholder treatment is put at 3.5 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 35% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -109%: lost 109¢ per shareholder dollar. Leverage 19%: owes 19¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Gain Therapeutics, Inc. lost about 109 cents for every dollar of shareholders' money. Leverage: it owed about 19 cents per dollar of assets, and net share issuance: its share count grew 44.1% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 25% of 315 in its family; net margin -40354.3%.
From the record
Gain Therapeutics, Inc.'s standing among 315 graded names in its industry family: revenue of $55 thousand in fiscal 2023 ranks in the bottom 6% by size; a net margin of -40354.3% ranks in the bottom 5%; revenue growth of 24.1% a year over the last 3 filed years ranks in the top 34% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
bottom 32% of 315 in its family for leadership; chief executive since 2024.
From the record
Gain Therapeutics, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Mack, Gene (CEO, President, as filed), filing under that title since 2024-08-12, 2.3 years (bottom 25% of its family); the 9 officers and directors filing in the last fifteen months have been on the record a median of 5.6 years (bottom 50%); 7 officer or director changes were reported on Form 8-K since 2023-11-13, against the 9 people in charge now (bottom 21%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
SI estimate 9.0/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Gain Therapeutics, Inc.'s room to expand is put at 9.0 of 10 with a confidence of 35 of 100, because read from one part only, cash less debt against assets, which ranks in the top 10% of 479 in its family; the record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue. A filing that carries the missing parts replaces this estimate with the filed reading.
What could actually drive growth from here?
bottom 40% of 306 in its family for growth drivers.
From the record
Gain Therapeutics, Inc.'s growth drivers, from the filed years to fiscal 2023: revenue grew 24.1% a year over the last three filed years against 24.1% over all 4, speeding up (top 40% of its family); the newest year grew -60.6% (bottom 12%); research spending grew 6.8% a year (top 43%); capital spending grew -38% a year (bottom 31%) (its annual reports). Gain Therapeutics, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
bottom 9% of 233 in its family for expectations against reality.
From the record
Gain Therapeutics, Inc.'s newest year against its own record: revenue of $55 thousand in fiscal 2023 came in 82.1% below the $309 thousand its prior three years' pace pointed to (bottom 9% of its family); net income of $22 million against a prior three-year average of $12 million (bottom 16%); a net margin of a loss larger than its revenue against losses larger than its revenue before (bottom 3%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made